DSM invests in IntegraGen
This article was originally published in The Tan Sheet
Executive Summary
The Netherlands-based firm has invested $2.6 mil. (€1 = $1.28) in IntegraGen, a French biotechnology company specializing in the development and delivery of genetic tests for rapid diagnosis and better treatment of complex diseases, DSM announces Nov. 7. "IntraGen's proprietary GenomeHIP technology platform identifies disease genes by allowing the rapid comparison of genomes of family members affected with the same disease," the release states. IntegraGen also "recognizes the potential of its know-how in personalized nutrition," which has led to a collaboration program in the area of weight management, the release says. Recently, DSM collaborated with the European Genetic Alliances Network and the International Genetic Alliance to promote health management and "the contribution of functional foods ingredients" to patient and consumer organizations (1"The Tan Sheet," Oct. 30, 2006, In Brief)...
You may also be interested in...
DSM preventive health collaboration
DSM Food Specialties is strengthening its work with patient organizations European Genetic Alliances Network (EGAN) and the International Genetic Alliance (IGA) to promote health management and "the contribution of functional food ingredients" to patient and consumer organizations, policy makers and the general public, according to a release from The Delft, The Netherlands-based ingredient firm. "This collaboration will help us gain better insight into patient needs in order to develop products that meet these needs," said Philip Rijken, the head of nutritional science. "Together we aim to further promote evidence-based development of functional food ingredients and nutritional products which are effective in optimizing and maintaining health in general or in reducing chronic/genetic disease risk"...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.